Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exploring options for improving healthcare.

Stanley S Wang1, Daniel N Mendelson, Kevin A Schulman

  • 1Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA. wangmdjd@yahoo.com

American Heart Journal
|December 24, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Importance of Age in Selecting a Testing Strategy for Stable Symptomatic Patients With Suspected Coronary Artery Disease.

Journal of the American Geriatrics Society·2026
Same author

Choosing Between CABG and PCI for 3-Vessel Coronary Disease: What's Cost Got to Do With It?

Journal of the American College of Cardiology·2026
Same author

Additive prognostic value of functional performance to coronary artery anatomy: the ISCHEMIA trial.

European heart journal. Cardiovascular Imaging·2026
Same author

Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease.

Journal of the American College of Cardiology·2025
Same author

Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.

Circulation·2025
Same author

Survival After Initial Stress Testing vs Anatomic Testing in Suspected Coronary Artery Disease: Long-Term Follow-Up of the PROMISE Randomized Clinical Trial.

JAMA cardiology·2025
Same journal

Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.

American heart journal·2026
Same journal

Revised Lipid-Lowering Therapy Guidelines in a Nationally Representative Sample.

American heart journal·2026
Same journal

Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023.

American heart journal·2026
Same journal

Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research Consortium.

American heart journal·2026
Same journal

THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

American heart journal·2026
Same journal

DOAC Score Among Patients Receiving Vitamin K Antagonists.

American heart journal·2026
See all related articles

Regulatory agencies like the US Food and Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS) often approve new medical technologies separately. This article explores options for improving collaboration between the FDA and CMS for greater regulatory efficiency.

Area of Science:

  • Health policy
  • Regulatory science
  • Medical technology assessment

Background:

  • Medical technologies require dual approval from the US Food and Drug Administration (FDA) and insurers like the Centers for Medicare and Medicaid Services (CMS) for clinical use.
  • Current regulatory processes are sequential and discrete, lacking collaboration between the FDA and CMS.

Framework:

  • The article stems from a 2002 conference discussing mechanisms to enhance regulatory collaboration between the FDA and CMS.
  • It examines key issues in the regulatory approval and coverage processes for new medical technologies.

Implementation:

  • Proposes options for improving regulatory efficiency through enhanced coordination between the FDA and CMS.
  • Discusses these proposals from the viewpoints of agency, academic, and industry stakeholders.

Related Experiment Videos

Implications:

  • Aims to foster greater synergy between regulatory approval and reimbursement pathways.
  • Potential to streamline the availability of innovative medical technologies for widespread clinical adoption.